dsm-firmenich AG

What they make

5 inputs dsm-firmenich AG supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

4 facilities

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Did you know2023

  Martek Biosciences (Columbia MD) — the company that invented and commercialized algal DHA, now wholly owned by DSM-Firmenich as the life'sDHA brand — was originally founded in 1985 with SBIR (Small Business Innovation Research) funding from NASA. NASA's goal was to develop compact, nutrient-dense food sources for astronauts on long-duration missions (where importing fish for omega-3 nutrition was impractical). Martek's researchers identified Schizochytrium microalgae as a high-DHA producer that could be grown in bioreactors without sunlight. The technology that failed to go to space (NASA's long-duration mission DHA program) became the dominant ingredient in newborn brain nutrition: life'sDHA is now added to infant formula sold in over 75 countries and is mandated in many. A NASA-funded space nutrition project, never used in space, now feeds the brains of millions of infants annually. DSM acquired Martek in 2011 for $1.09 billion — a remarkable valuation for a company selling algae oil to baby formula makers.

  DSM-Firmenich ↗

• Concentration2023

  DSM-Firmenich's near-monopoly on infant formula DHA/ARA began with Martek Biosciences (Columbia MD), founded in 1985 by the NASA contractor and microbiologist David Kyle. Kyle developed microalgae fermentation technology to produce DHA (docosahexaenoic acid) — an omega-3 essential for infant brain development — from marine microalgae that naturally synthesize it. Martek's insight: use land-based fermentation of marine microalgae to produce the same DHA found in breast milk, without fish. Martek licensed its technology to Mead Johnson (now Reckitt) and Abbott Nutrition in the late 1990s. By 2002, DHA/ARA was added to infant formula in the US (Abbott's Similac, Mead Johnson's Enfamil), Europe, and Japan. For approximately 15 years, Martek was the sole commercial-scale source of FDA-qualified algal DHA and ARA for infant formula globally — a single Maryland biotechnology company was the functional monopoly supplier of ingredients added to every can of infant formula sold in the US. DSM acquired Martek in 2011 for $1.1B. FDA's 2023 infant formula rule making DHA mandatory for all US formula cemented DSM-Firmenich's position as an essential ingredient supplier for the entire US infant formula market — every formula manufacturer must source FDA-compliant DHA, and DSM holds the dominant share of qualified supply.

  DSM-Firmenich ↗

• Incident2015

  Firmenich SA's most consequential relationship — supplying the fragrance compound for Chanel No. 5 — is also the fragrance industry's most closely guarded trade secret. Chanel No. 5, created by perfumer Ernest Beaux in 1921, was one of the first fine fragrances to use synthetic aroma chemicals at high concentration (specifically aldehyde C-11 undecylenic and aldehyde C-12 lauric — the waxy, 'soapy-clean' character that made No. 5 revolutionary). Firmenich has supplied the Chanel No. 5 fragrance compound — a pre-blended aromatic composition delivered to Chanel — since the early 20th century, making it a multi-decade sole-source relationship for the world's most famous fragrance. When IFRA restricted oakmoss and treemoss (Evernia prunastri and Evernia furfuracea — natural lichen extracts that provided No. 5's distinctive mossy base) due to allergenicity concerns (IFRA's 2003 and subsequent amendments), Chanel and Firmenich were forced to reformulate No. 5 while legally maintaining its identity. The reformulation required replacing oakmoss with synthetic alternatives while preserving the olfactory signature that consumers recognized — a 'reformulation under cover' that Chanel publicly denied had occurred for years. Consumer fragrance bloggers and 'frag-heads' on forums documented the change through blind comparison tests of vintage vs. contemporary bottles. The episode illustrates how IFRA ingredient restrictions can force silent reformulation of iconic products that the brand cannot publicly acknowledge.

  International Fragrance Association (IFRA) ↗

• Chokepoint2007

  Martek Biosciences filed extensive patents on the use of algal DHA and fungal ARA in infant formula covering not just its specific production strains but the general concept of adding these fatty acids from microbial sources. These 'method of use' patents created a blocking position preventing competitors from supplying algal DHA or fungal ARA to formula manufacturers for nearly 15 years. The patents began expiring around 2017-2019, finally opening the market to competitors such as Corbion.

  FoodNavigator ↗